Company intelligence / Profile preview
Shanghai Kaibao Pharmaceutical
Shanghai, Chinaxykb.com ↗
- Ownership
- Private
- Employees
- ~1225
- Development stage
- Other
01
Overview
Shanghai Kaibao Pharmaceutical has several commercialized products in China, primarily focused on traditional Chinese medicines such as Tanreqing injection for respiratory infections. The company also has a pipeline with clinical-stage assets including dulanermin in Phase 3 for advanced lung cancer, 20(S)-protopanoxadiol in Phase 2 for depressive disorder, and YKRH‑00020 in Phase 1 for productive cough.
- Therapeutic areas
- PsychiatryOncologyPulmonologyInfectious Diseases
- Modalities
- Herbal medicineSmall molecule drug
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
dulanermin is co-developed with Shanghai Gebaide Biotechnology Co., Ltd.
Beyond the preview
Go deeper on Shanghai Kaibao Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Kaibao Pharmaceutical.